Alvotech Faces Scrutiny over Manufacturing Issues
National shareholder rights firm Hagens Berman is currently analyzing Alvotech (NASDAQ: ALVO) regarding potential misrepresentations in their disclosures tied to manufacturing operations and the regulatory status of their primary biosimilar candidate, AVT05.
Impact of FDA's Complete Response Letter
The investigation stems from a drastic 34% decline in Alvotech’s stock following the company's announcement about receiving a "Complete Response Letter" (CRL) from the FDA. This letter highlighted significant deficiencies that prompted declines in investors' confidence. Alvotech's stock lost considerable value almost immediately, prompting concern among shareholders.
Understanding the Investigation
Hagens Berman is concentrating on whether Alvotech provided misleading information regarding the competence of its Iceland manufacturing facility to adhere to FDA regulations. The firm’s management had previously expressed optimistic revenue expectations for AVT05, forecasting up to $700 million in revenue for the year 2025.
Details of the Stock Price Volatility
On November 2, 2025, Alvotech shocked investors when it announced the FDA decision to issue a CRL for AVT05, revealing deficiencies identified during an inspection of their Reykjavik plant conducted in July 2025. This led to a dramatic reassessment of its anticipated revenue for 2025, resulting in an alarming 58% cut in its adjusted EBITDA outlook, causing the stock to plummet from $7.65 to $5.03 in one trading session.
Investor Concerns Rise
Reed Kathrein, leading the investigation for Hagens Berman, expressed, "We are exploring whether Alvotech was aware of these significant manufacturing issues prior to announcing them publicly." These revelations intensify investor scrutiny and raise questions about corporate governance at Alvotech.
Navigating the Crisis
With the current predicament, investors who have suffered losses are encouraged to engage with Hagens Berman to discuss potential claims. The ongoing inquiry aims to ascertain accountability regarding the critical information shared by Alvotech with investors, especially pertaining to the manufacturing readiness of its plant.
How to Assist the Investigation
Anyone with non-public information about Alvotech's operations or internal communications with the FDA is encouraged to come forward. The investigation seeks to gather insights from those privy to the company’s dealings, particularly concerning the manufacturing status of their lead biosimilar.
Whistleblower Information
Whistleblowers with knowledge about Alvotech’s compliance or internal standards have avenues to contribute to the investigation, potentially benefiting from the SEC’s whistleblower program, which offers financial incentives for reporting original information that reinforces regulatory scrutiny.
Frequently Asked Questions
What is the investigation about?
Hagens Berman is examining Alvotech for potentially misleading statements regarding their biosimilar manufacturing capabilities and FDA approval chances.
What does an FDA CRL signify?
A Complete Response Letter indicates that an application is not approved as submitted, signaling deficiencies in manufacturing that prompted a major drop in Alvotech's stock valuation.
How can I participate in the Alvotech inquiry?
If you possess information regarding Alvotech’s Reykjavik facility or internal correspondence, contact Hagens Berman for an opportunity to assist in the investigation.
What are the investor protections available?
Investors are encouraged to be vigilant about disclosures and seek guidance when discrepancies arise, especially in cases of significant stock movements.
Where can I find more information?
For continuous updates about the investigation and other related developments, stay connected with Hagens Berman’s communications and community outreach efforts.
